Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Average Rating of “Hold” by Analysts

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) have been assigned an average rating of “Hold” from the thirteen ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $19.7273.

A number of research analysts have commented on the company. JMP Securities set a $12.00 price objective on Bicycle Therapeutics in a report on Friday, October 31st. Citigroup reaffirmed an “outperform” rating on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Citizens Jmp lifted their price target on shares of Bicycle Therapeutics from $10.00 to $12.00 and gave the company a “market outperform” rating in a report on Friday, October 31st. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Monday, December 22nd. Finally, Truist Financial began coverage on shares of Bicycle Therapeutics in a research note on Monday, November 24th. They set a “hold” rating and a $10.00 target price on the stock.

Bicycle Therapeutics Stock Up 0.3%

NASDAQ:BCYC opened at $6.80 on Friday. The firm has a market capitalization of $471.70 million, a P/E ratio of -1.88 and a beta of 1.47. The company has a fifty day moving average of $7.09 and a 200 day moving average of $7.45. Bicycle Therapeutics has a 52 week low of $6.03 and a 52 week high of $15.47.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings data on Thursday, October 30th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.24. The firm had revenue of $11.73 million for the quarter, compared to analysts’ expectations of $8.25 million. Bicycle Therapeutics had a negative net margin of 884.51% and a negative return on equity of 36.05%. As a group, analysts anticipate that Bicycle Therapeutics will post -3.06 EPS for the current year.

Insiders Place Their Bets

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,231 shares of Bicycle Therapeutics stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $8.41, for a total transaction of $27,172.71. Following the sale, the chief executive officer directly owned 475,310 shares of the company’s stock, valued at approximately $3,997,357.10. The trade was a 0.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last quarter, insiders sold 8,527 shares of company stock worth $71,738. Insiders own 8.50% of the company’s stock.

Institutional Investors Weigh In On Bicycle Therapeutics

Several hedge funds have recently made changes to their positions in the company. Assetmark Inc. grew its stake in Bicycle Therapeutics by 74.9% in the third quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock worth $28,000 after purchasing an additional 1,552 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Bicycle Therapeutics by 1.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 140,492 shares of the company’s stock valued at $976,000 after buying an additional 2,243 shares in the last quarter. Virtus Investment Advisers LLC grew its position in shares of Bicycle Therapeutics by 32.6% in the 2nd quarter. Virtus Investment Advisers LLC now owns 10,821 shares of the company’s stock worth $75,000 after buying an additional 2,659 shares during the period. Ameriprise Financial Inc. grew its position in shares of Bicycle Therapeutics by 21.7% in the 3rd quarter. Ameriprise Financial Inc. now owns 14,972 shares of the company’s stock worth $116,000 after buying an additional 2,668 shares during the period. Finally, Ausdal Financial Partners Inc. bought a new position in shares of Bicycle Therapeutics in the 2nd quarter worth about $70,000. 86.15% of the stock is currently owned by institutional investors.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.